CoreAge Rx review: identify the offering before comparing TB-500

On this page

At a glance / CoreAge Rx

Our take

CoreAge’s checked lineup does not supply the TB-500 ingredient match this comparison needs. A general peptide category cannot establish a fragment, preparation or route that is not actually listed. Until a specific offer is documented, treat this as a brand-level service review and keep its unresolved renewal and refund terms separate from any assumed TB-500 cost.

Review scope: Provider brand; target-product availability not verified
Commercial relationship: Approved affiliate partner; product placement not activated
State and pharmacy match: Confirm for the exact proposed prescription
Refund terms to resolve: FAQ promises a full denial refund; the detailed policy allows a $50–$100 consultation deduction.
Renewal terms to resolve: FAQ says no automatic rebilling; detailed terms permit subscription renewals.

Useful details

Public service and policy information can be examined before an assessment.
The brand and the proposed product can be evaluated separately.

What to weigh

The checked catalog does not establish the target peptide offering.
Refund and renewal wording requires plan-specific confirmation.
The dispensing pharmacy and patient-state eligibility need verification.

A review of published information, not a treatment experience or a clinical quality rating. Source check: 2026-10-28.

The first question

For a TB-500 comparison, the provider name is only the first field. Ingredient identity, formulation and route must follow. CoreAge is an affiliate partner for this site, but the checked catalog did not establish that product match. Do not interpret the presence of other peptide-related services as a description of TB-500 or of a specific thymosin fragment. The review therefore concerns the brand’s public care and billing information, with the product question left open.

How to use this review

If CoreAge later announces a TB-500 offering, preserve the complete ingredient description before updating this comparison. A shorthand label is not enough to connect a commercial preparation to a research paper. Ask for the exact sequence or ingredient identity, formulation and proposed route, then evaluate the study and product separately. A clinician should explain why that particular offering is being considered rather than relying on the reputation of a different product in the catalog.

An ingredient match is still missing

CoreAge's checked catalog describes other wellness offerings, including sermorelin and NAD+. It did not provide the TB-500 product description needed for this comparison. An article discussing peptide combinations is educational coverage, not a stock record. Ask for a current listing that identifies the actual ingredient, formulation and route; preserve the full wording rather than shortening it to TB-500 yourself.

Find the terms for that exact proposal

If a relevant offer appears, ask which agreement governs it. The FAQ and detailed policy differ on renewal and refund language. Have CoreAge explain what you would pay if an assessment ends without the requested prescription, and when an order becomes final. A reply about the brand's general process is insufficient if the product-specific payment terms remain unclear. The current availability briefing explains the additional identity and route questions a policy reference creates.

Compare a quote, not a neighboring product

A published starting rate for a different ingredient cannot supply a missing TB-500 price. Request an itemized quote only after the formulation and route are identified. Keep any required assessment, follow-up and delivery charges visible, together with the payment interval and minimum commitment. Do not assume two plans are comparable because both carry a monthly heading.

The next useful step

Ask CoreAge whether it currently has the exact TB-500-related offering you are researching in your state, and request its product page. Until that match is documented, use this review to understand the brand rather than choose a TB-500 source. A different product belongs in a separate clinical conversation, not in the same comparison row.

Common questions

Which TB-500 ingredient does the checked catalog identify?

The reviewed lineup did not establish a current TB-500 offering, so it cannot settle the full-length-versus-fragment or formulation question for such a prescription.

Can the current sermorelin listing answer that question?

No. Sermorelin is separately named in the catalog. It does not establish an ingredient description, price or clinical equivalence for TB-500.

What should I clarify about the first payment?

Ask which consultation charge applies and whether the plan renews. The FAQ and detailed policy disagree about automatic rebilling and full refunds after a denied prescription.

Sources & further reading

Primary research, provider documents and policy sources used in this article. Sources do not endorse this publication.

Source review: 2026-10-28. Provider terms and policy documents can change.

A useful next step

Compare the care details Put written quotes side by side